Sign in

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

e-ISSN 1726-9148
p-ISSN 1726-913X
Authors GuideSubmit manuscript
Cover image of the article: Vascular Cell Adhesion Molecule-l (VCAM-l) in Graves' Disease: Its Association to Thyroid Status and Thyroid Receptor Stimulating Antibodies

Image Credit:Int J Endocrinol Metab

Outline

Vascular Cell Adhesion Molecule-l (VCAM-l) in Graves' Disease: Its Association to Thyroid Status and Thyroid Receptor Stimulating Antibodies

Authors

Wan Nazaimoon WM1,*, Ismail IS2, Tan HJ3, Kamaruddin NA3, Khalid AK3
1Institute for Medical Research, nazaimoon@imr.gov.my, Malaysia
2University Malaya Medical Center, Malaysia
3Faculty of Medicine, Universiti Kebangsaan, Malaysia
*Corresponding Author: Institute for Medical Research, nazaimoon@imr.gov.my, Malaysia. Email: nazaimoon@imr.gov.my
International Journal of Endocrinology and Metabolism:Vol. 2, issue 2; 66-73
Published online:Jan 01, 2004
Article type:Research Article
How to Cite:Nazaimoon WM W, IS I, HJ T, NA K, AK K. Vascular Cell Adhesion Molecule-l (VCAM-l) in Graves' Disease: Its Association to Thyroid Status and Thyroid Receptor Stimulating Antibodies. Int J Endocrinol Metab. 2004;2(2):. doi:

Abstract

Soluble vascular cell adhesion molecule-1 (sVCAM-1) and intercellular adhesion molecule-1 (sICAM-1) have been shown to be elevated in patients with Graves'disease and may play significant roles in the pathogenesis of the disease. The objective of this study was to measure the levels of sVCAM-1, sICAM-l, IL-6 and thyroid receptor stimulating antibodies (TRAb) in a cohort of hyperthyroid patients and determine their associations to thyroid hormones status, before and after 3 months thexapy with carbimazole.

Materials and Methods:

Patients were given fixed daily dose of 20 mg carbimazole for 3 months and blood samples were collected at baseline and end of the study. Thirty-eight patients were recruited from the Endocrine Clinic, Hospital Universiti Kebangsaan Malaysia, consisting of 26 females and 12 males, age ranging from 16 to 65 years. Blood samples collected before and at end of study were analysed for TSH, Free TJ, Free T4J thyroid receptor stimulating antibodies (TRAb), sVCAM-1, sICAM-1 and lL-6.

Results:

TRAb level of ?10 to U/L was taken to be negative, while TRAb level of >10 U/L was considered as positive. Twenty-six patients (68%) were TRAb positive (TRAb+) and 12 patients (30%) were TRAb negative (TRAb-). Median TRAb in TRAb+ patients was 23 UIL at baseline, declining to 16.7 U/L (p<0.00l) in the third 3 month. Sexum sVCAM-1 levels were significantly elevated in TRAb+ patients compared to TRAb-(860 versus 499 nglmL, p<0.00l). The level decreased significantly to 537 nglmL with treatment but remained higher than in TRAb-patients (p=0.003). Irrespective of TRAb status, all but one patient had elevated serum sICAM-l levels that remained unaffected by carbimazole therapy. In contrast, IL-6 levels of hyperthyroid patients were within the reference range of 1.+14.1 pglmL. Baseline and post-treatment sVCAM-l, and not TRAb levels, were significantly correlated to thyroid hormones.

Conclusion:

Compared to other inflammatory markers, sVCAM-l showed significant correlation to thyrOid stimulating antibodies and was most sensitive to changes in thyroid status. The significance of these findings in relation to Graves' disease warrants further investigation.

Highlights

KeywordsVCAM-1GravesdiseaseTRAbInflammation

Full Text

Full text is available in PDF

Copyright

© 2004, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

12
Oct
2019
Systemic Thyroid Hormone Status in Treated Graves’ Disease

Systemic Thyroid Hormone Status in Treated Graves’ Disease

Fereidoun Azizi,
Atieh Amouzegar,
Maryam Tohidi,
Mehdi Hedayati,
Leila Cheraghi,
Yadollah Mehrabi
PDF

Azizi F, Amouzegar A, Tohidi M, Hedayati M, Cheraghi L, et al. Systemic Thyroid Hormone Status in Treated Graves’ Disease. Int J Endocrinol Metab. 2019;17(4):e95385. doi: https://doi.org/10.5812/ijem.95385

14
Jun
2020
Long-Term Antithyroid Drug Treatment: Trends in Serum TSH and TSH Receptor Antibody Changes in Patients with Graves’ Disease

Long-Term Antithyroid Drug Treatment: Trends in Serum TSH and TSH Receptor Antibody Changes in Patients with Graves’ Disease

Ken Okamura,
Sachiko Bandai,
Megumi Fujikawa,
Kaori Sato,
Hiroshi Ikenoue,
Takanari Kitazono
PDF

Okamura K, Bandai S, Fujikawa M, Sato K, Ikenoue H, et al. Long-Term Antithyroid Drug Treatment: Trends in Serum TSH and TSH Receptor Antibody Changes in Patients with Graves’ Disease. Int J Endocrinol Metab. 2020;18(Suppl):e101139. doi: https://doi.org/10.5812/ijem.101139

30
Apr
2005
Are Serum Thyrotropin level and Subclinical Hypothyroidism Predisposing Factors for Coronary Artery Disease?

Are Serum Thyrotropin level and Subclinical Hypothyroidism Predisposing Factors for Coronary Artery Disease?

M Shams,
MB Sharif-Kazemi,
KB Lankarani,
AS Sadegholvad,
GR Omrani
PDF

Shams M, Sharif-Kazemi M, Lankarani K, Sadegholvad A, Omrani G. Are Serum Thyrotropin level and Subclinical Hypothyroidism Predisposing Factors for Coronary Artery Disease?. Int J Endocrinol Metab. 2005;3(2):. doi:

31
Jan
2026
Sustained Control of Hyperthyroidism in Graves’ Disease: Comparison of Thyroidectomy and Long-Term Antithyroid Treatment

Sustained Control of Hyperthyroidism in Graves’ Disease: Comparison of Thyroidectomy and Long-Term Antithyroid Treatment

Hengameh Abdi,
Miralireza Takyar,
Ladan Mehran,
Safdar Masoumi,
Atieh Amouzegar,
Fereidoun Azizi
PDF

Abdi H, Takyar M, Mehran L, Masoumi S, Amouzegar A, et al. Sustained Control of Hyperthyroidism in Graves’ Disease: Comparison of Thyroidectomy and Long-Term Antithyroid Treatment. Int J Endocrinol Metab. 2026;24(1):e164940. doi: https://doi.org/10.5812/ijem-164940

1
Dec
2012
Management of Subclinical Hyperthyroidism

Management of Subclinical Hyperthyroidism

Silvia Santos Palacios,
Eider Pascual-Corrales,
Juan Carlos Galofre
PDF

Santos Palacios S, Pascual-Corrales E, Galofre JC. Management of Subclinical Hyperthyroidism. Int J Endocrinol Metab. 2012;10(2):. doi: https://doi.org/10.5812/ijem.3447

More by these authors

Wan Nazaimoon WMPubMedScholar
Ismail ISPubMedScholar
Tan HJPubMedScholar
Kamaruddin NAPubMedScholar
Khalid AKPubMedScholar

Find related work

PubMed
Google Scholar
Create citation alert
Download PDF3.79 MB
Share
Cited by
Metrics
Comments
Number of Comments:0